Evidence map›Paper›PMID 27422512›Full record

ReviewAdvances in nutrition (Bethesda, Md.)2016

Impact of Cranberries on Gut Microbiota and Cardiometabolic Health: Proceedings of the Cranberry Health Research Conference 2015.

Jeffrey B Blumberg, Arpita Basu, Christian G Krueger, Mary Ann Lila, Catherine C Neto, Janet A Novotny, Jess D Reed, Ana Rodriguez-Mateos, Cheryl D Toner

Open access · hybridAbstract readReview
In one paragraph

Review in Advances in nutrition (Bethesda, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Lyophilized Maqui (Antioxidants (Basel, Switzerland) · 2021
    Article
  20. Cranberry (AIMS microbiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Jeffrey B BlumbergJean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA; jeffrey.blumberg@tufts.edu.
Arpita BasuOklahoma State University, Stillwater, OK;
Christian G KruegerComplete Phytochemical Solutions, LLC, Cambridge, WI; University of Wisconsin-Madison, Madison, WI;
Mary Ann LilaNorth Carolina State University, Kannapolis, NC;
Catherine C NetoUniversity of Massachusetts at Dartmouth, Dartmouth, MA;
Janet A NovotnyUSDA Beltsville Human Nutrition Research Center, Beltsville, MD;
Jess D ReedComplete Phytochemical Solutions, LLC, Cambridge, WI; University of Wisconsin-Madison, Madison, WI;
Ana Rodriguez-MateosUniversity of Düsseldorf, Düsseldorf, Germany;
Cheryl D TonerThe Cranberry Institute, Carver, MA; and CDT Consulting, LLC, Herndon, VA.
University of Wisconsin–Madison · USBeltsville Human Nutrition Research Center · USCranberry Institute · USDavid H. Murdock Research Institute · USHeinrich Heine University Düsseldorf · DEOklahoma State University · USTufts University · USUniversity of Massachusetts Dartmouth · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in cranberry research have expanded the evidence for the role of this Vaccinium berry fruit in modulating gut microbiota function and cardiometabolic risk factors. The A-type structure of cranberry proanthocyanidins seems to be responsible for much of this fruit's efficacy as a natural antimicrobial. Cranberry proanthocyanidins interfere with colonization of the gut by extraintestinal pathogenic Escherichia coli in vitro and attenuate gut barrier dysfunction caused by dietary insults in vivo. Furthermore, new studies indicate synergy between these proanthocyanidins, other cranberry components such as isoprenoids and xyloglucans, and gut microbiota. Together, cranberry constituents and their bioactive catabolites have been found to contribute to mechanisms affecting bacterial adhesion, coaggregation, and biofilm formation that may underlie potential clinical benefits on gastrointestinal and urinary tract infections, as well as on systemic anti-inflammatory actions mediated via the gut microbiome. A limited but growing body of evidence from randomized clinical trials reveals favorable effects of cranberry consumption on measures of cardiometabolic health, including serum lipid profiles, blood pressure, endothelial function, glucoregulation, and a variety of biomarkers of inflammation and oxidative stress. These results warrant further research, particularly studies dedicated to the elucidation of dose-response relations, pharmacokinetic/metabolomics profiles, and relevant biomarkers of action with the use of fully characterized cranberry products. Freeze-dried whole cranberry powder and a matched placebo were recently made available to investigators to facilitate such work, including interlaboratory comparability.

Indexed as

Health PromotionHeart DiseasesMetabolic DiseasesVaccinium macrocarponAnimalsAnti-Infective AgentsBiofilmsDietFruitGastrointestinal MicrobiomeHumansInflammationLipidsOxidative StressPhytochemicalsPlant ExtractsAnti-Infective AgentsLipidsPhytochemicalsPlant ExtractsProanthocyanidinsantimicrobialcardiometaboliccranberrymicrobiomeproanthocyanidins

Identifiers

PMID27422512
PMCPMC4942875
OpenAlexW2470027118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.